Boehringer Ingelheim's Nerandomilast Trial for Fibrosing ILD Shows Potential for Disease Progression
A clinical trial is underway to evaluate the efficacy of nerandomilast in patients with fibrosing interstitial lung disease at risk for progression.
Therapeutic Area
Therapeutic area intelligence for Fibrosing Interstitial Lung Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.